Background Age is the strongest risk factor for dementia and there is considerable interest in
identifying scalable, blood-based biomarkers in predicting dementia. We examined the role …

Background Blood-based biomarkers for dementia are gaining attention due to their non-
invasive nature and feasibility in regular healthcare settings. Here, we explored the …

Background Plasma metabolomic profile is disturbed in dementia patients, but previous
studies have discordant conclusions. Methods Circulating metabolomic data of 110,655 …

Identifying circulating metabolites associated with dementia, cognition, and brain volume
may improve the understanding of dementia pathogenesis and provide novel insights for …

Introduction Recently, quantitative metabolomics identified a panel of 10 plasma lipids that
were highly predictive of conversion to Alzheimer's disease (AD) in cognitively normal older …

Introduction Metabolomics provide a promising tool to understand the pathogenesis and to
identify novel biomarkers of dementia. This study aimed to determine circulating metabolites …

Background: Currently, there is no objective, clinically available tool for the accurate
diagnosis of Alzheimer's disease (AD). There is a pressing need for a novel, minimally …

Aims: This study compared serum metabolites of demented patients (Alzheimer's disease
and vascular dementia) and controls, and explored serum metabolite profiles of …

Alzheimer's dementia (AD) begins many years before its clinical symptoms. Metabolic
dysfunction represents a core feature of AD and cognitive impairment, but few metabolomic …

Introduction Blood metabolomics‐based biomarkers may be useful to predict measures of
neurocognitive aging. Methods We tested the association between 707 blood metabolites …